May 30, 2017 · Interluekin-1 Receptor Antagonist Protein (IRAP) therapy is a branch of regenerative medicine used to treat the effects of degenerative joint disease in horses. For years, trainers and owners have battled the effects of arthritis in their horse’s joints.

IRAP aims to block, or tie-up, IL-1, a potent cytokine that causes a pro-inflammatory state. Mechanism: Aims to up-regulate Interleukin Receptor Antagonist Protein (IRAP) to block and tie-up IL-1 before it can attach to the joint capsule and initiate the “inflammatory cascade”.

Jul 30, 2023 · IRAP therapy involves injecting a protein called interleukin-1 receptor antagonist protein (IRAP) directly into the affected joint or tendon. IRAP is derived from the horse's own blood - it is produced naturally in response to injury or inflammation.

What is IRAP Therapy for Horses? A relatively new therapy in the management of equine arthritis is IRAP Therapy. Horse owners today have very little knowledge about IRAP and even less of an understanding of that this medical treatment is all about.

IRAP® was developed to counteract the inflammatory protein interleukin-1 that is produced in the joint during synovitis and to slow the progression of OA. It prevents IL-1 from binding to IL-1 receptors on tissues within the joint, and therefore blocks the action of and stops the damage caused by IL-1 in the joint.

The IRAP system has been designed to stimulate the horses’ own white blood cells to produce anti-inflammatory mediators and enzymes, specifically Interleukin 1 receptor antagonist protein (IRAP), which can reduce the inflammation present as a result of degenerative joint disease.

IRAP stands for Interluekin-1 Receptor Antagonist Protein and recently is being referred to as autologous conditioned serum. Equine athletes are susceptible to musculoskeletal injuries and osteoarthritis or degenerative joint disease. Osteoarthritis is a common cause of …

May 26, 2014 · IRAP blocks the effects of IL-1 by acting directly on the IL-1 receptor in cells and inhibiting IL-1 attachment to the receptor. The source of IRAP was found to be particular types of white blood cells, monocytes and macrophages. By …

A novel therapy called IRAP®, Interleukin-1 Receptor Antagonist Protein, is now available and showing promising results for the treatment of osteoarthritis in horses. Equine athletes are susceptible to musculoskeletal injuries and osteoarthritis (OA), also …

Interleukin-1 receptor antagonist protein (IRAP) is a potent anti-inflammatory used in the management of osteoarthritis in horses. Whole blood is taken from the horse into the IRAP® syringe, which contains specially coated glass beads.